Navigation Links
Intact Medical Corporation's Intact(R) Excise XL Receives 510(K) Marketing Clearance from the FDA
Date:9/16/2008

ign lesion removals performed in the U.S. each year. Within this population, we expect the introduction of the Excise XL to result in increased usage of the System, as it provides physicians with a greater measure of flexibility in removing and diagnosing suspicious lesions of the breast. The new, larger capture basket will also allow physicians to remove the entire lump with the non-invasive Intact(R) System, versus an open surgical procedure, which is commonly used with larger lesions."

About Intact Medical Corporation

Founded in 1998, and based in Natick, Massachusetts, Intact Medical Corporation is a privately held company focused on the design, development and marketing of innovative, minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. The Company's lead product, the Intact Breast Lesion Excision System, received market clearance from the Food and Drug Administration in June 2001. Initial products are targeted at

breast biopsy and the excision of benign lesions, potentially obviating the need for open surgical excisions. In August 2005, the company received expanded approval for the System, allowing its use to obtain tissue samples for histologic examination with partial or complete removal of an imaged abnormality, or partial removal of a palpable abnormality that has been classified as benign.

For more details on the Company, visit http://www.intactmedical.com

Contact:

Intact Medical Corporation

Christopher Bleck, President & CEO

508-655-7820

Rx Communications Group

Paula Schwartz (investors) 917-322-2216

Eric Goldman (media) 917-322-2563


'/>"/>
SOURCE Intact Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014  Neogen Corporation (Nasdaq: NEOG ... quarter of its 2015 fiscal year, which ended Aug. ... net income of $7,839,000 in the first quarter of ... Oct. 30, 2013, earnings per share in the current ... First quarter revenues increased 15% to $67,599,000, ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
(Date:9/21/2014)... September 21, 2014 Chemical Sciences ... challenges such as clean air and safe water, ... natural products. Chemists, environmentalists, food scientists, educators, and ... research in the field of Chemistry for the ... Sciences is one of the fastest emerging Sciences, ...
Breaking Biology Technology:Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3
... Inc. (PDL, the Company) (NASDAQ: PDLI ) today ... other conditions, $135 million aggregate principal amount of new convertible ... statement filed with the U.S. Securities and Exchange Commission (SEC) ... the underwriters a 13-day overallotment option to purchase up to ...
... SPRING, Md., May 9, 2011 The U.S. Food and ... public relating to the development of a user fee ...   (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... as a microorganism, plant, or animal cell, while small ...
... 2011 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that the U.S. Securities and Exchange ... Statement relating to the previously announced acquisition of TomoTherapy ... registration statement will first be mailed to TomoTherapy shareholders ...
Cached Biology Technology:PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 3SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 4
(Date:9/22/2014)... fishes that manufacture their own "antifreeze" proteins to ... an unfortunate side effect, researchers report: The protein-bound ... melting even when temperatures warm. , The ... the National Academy of Sciences . , "We ... of the evolution of antifreeze proteins in Antarctic ...
(Date:9/22/2014)... 2014)The Brain & Behavior Research Foundation ... Young Investigator Grants valued at more than ... most promising young scientists. Recipients of the ... will seek to identify causes, improve treatments ... that affect one in four people, including ...
(Date:9/22/2014)... more useful in homes, if they could locate people, ... with cameras and lasers, which have difficulty reliably recognizing ... clutter. A complementary way robots can "sense" what is ... frequency radio-frequency identification (UHF RFID) tags. Inexpensive self-adhesive tags ... to search a room for the correct tag,s signal, ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3
... Karen Burg and her colleagues in the Institute for ... means of studying the complex behavior of cancer cells ... way doctors treat the disease. With support from ... the researchers are building scaffolds that mimic the three-dimensional ...
... diseases is a hot area of scientific research, primarily ... the context of atherosclerotic disease. Scientists have engineered a ... about the conditions under which nanoparticles accumulate in the ... of myocardial infarction and stroke. In the research, ...
... blood platelets and bone marrow cells to deliver potentially ... genetic disorder Hurler syndrome an often fatal condition ... Scientists from Cincinnati Children,s Hospital Medical Center and the ... their unique strategy for treating the disease the week ...
Cached Biology News:In vitro innovation: Testing nanomedicine with blood cells on a microchip 2In vitro innovation: Testing nanomedicine with blood cells on a microchip 3Mouse study shows gene therapy may be possible cure for Hurler syndrome 2
... complete kit contains enough separation ... a total of 5 x ... includes the StemSep red magnet ... and buffers for the specific ...
... fast and specific detection of chromosomal sequences ... hybridisation time ( Works ... Multiplex capability Available with different tags ... available with different labels. Related Content: ...
... dehydrogenase catalyzes a reversible reaction between ... with NAD as a coenzyme. GPDH ... progenitor cells into adipocytes and, thus, ... been used as an index for ...
...
Biology Products: